

- can provide new insights to our understanding of symptomatic and asymptomatic urethritis. *Int J STD AIDS* 2006;**17**:289–95.
- 21 **Keane FE**, Thomas BJ, Whitaker L, et al. An association between non-gonococcal urethritis and bacterial vaginosis and the implications for patients and their sexual partners. *Genitourin Med* 1997;**73**:373–7.
  - 22 **Horner PJ**, Taylor-Robinson D. A role for leucocyte esterase testing in conjunction with non-invasive screening using nucleic acid amplification tests for asymptomatic men attending departments of Genitourinary Medicine. *Int J STD AIDS* 2007;**18**:73–4.
  - 23 **Zenilman JM**, Miller WC, Gaydos C, et al. LCR testing for gonorrhoea and chlamydia in population surveys and other screenings of low prevalence populations: coping with decreased positive predictive value. *Sex Transm Infect* 2003;**79**:94–7.
  - 24 **Palmer HM**, Mallinson H, Wood RL, et al. Evaluation of the specificities of five DNA amplification methods for the detection of *Neisseria gonorrhoeae*. *J Clin Microbiol* 2003;**41**:835–7.
  - 25 **Akduman D**, Ehret JM, Messina K, et al. Evaluation of a strand displacement amplification assay (BD ProbeTec-SDA) for detection of *Neisseria gonorrhoeae* in urine specimens. *J Clin Microbiol* 2002;**40**: 281–3.
  - 26 **Diemert DJ**, Libman MD, Lebel P. Confirmation by 16S rRNA PCR of the COBAS AMPLICOR CT/NG test for diagnosis of *Neisseria gonorrhoeae* infection in a low-prevalence population. *J Clin Microbiol* 2002;**40**:4056–9.
  - 27 **Johnson AM**, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. *Lancet* 2001;**358**:1835–42.
  - 28 **Tait IA**, Hart CA. *Chlamydia trachomatis* in non-gonococcal urethritis patients and their heterosexual partners: routine testing by polymerase chain reaction. *Sex Transm Infect* 2002;**78**:286–8.
  - 29 **Quinn TC**, Gaydos C, Shepherd M, et al. Epidemiologic and microbiologic correlates of *Chlamydia trachomatis* infection in sexual partnerships. *JAMA* 1996;**276**:1737–42.
  - 30 **Clad A**, Prillwitz J, Hintz KC, et al. Discordant prevalence of *Chlamydia trachomatis* in asymptomatic couples screened using urine ligase chain reaction. *Eur J Clin Microbiol Infect Dis* 2001;**20**:324–8.
  - 31 **Department of Health**. A health promoting NHS: transforming sexual health services. In: *Choosing health: making healthy choices easier*. <http://www.dh.gov.uk/assetRoot/04/09/47/64/04094764.pdf>, pp 145–7 (accessed 6 Mar 2007).

### BMJ Clinical Evidence—Call for contributors

*BMJ Clinical Evidence* is a continuously updated evidence-based journal available worldwide on the internet which publishes commissioned systematic reviews. *BMJ Clinical Evidence* needs to recruit new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine, with the ability to write in a concise and structured way and relevant clinical expertise.

#### Areas for which we are currently seeking contributors:

- Secondary prevention of ischaemic cardiac events
- Acute myocardial infarction
- MRSA (treatment)
- Bacterial conjunctivitis

However, we are always looking for contributors, so do not let this list discourage you.

#### Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) valid studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we will publish.
- Writing the text to a highly structured template (about 1500–3000 words), using evidence from the final studies chosen, within 8–10 weeks of receiving the literature search.
- Working with *BMJ Clinical Evidence* editors to ensure that the final text meets quality and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available. The *BMJ Clinical Evidence* in-house team will conduct the searches for contributors; your task is to filter out high quality studies and incorporate them into the existing text.
- To expand the review to include a new question about once every 12 months.

In return, contributors will see their work published in a highly-rewarded peer-reviewed international medical journal. They also receive a small honorarium for their efforts.

If you would like to become a contributor for *BMJ Clinical Evidence* or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to [CECommissioning@bmjgroup.com](mailto:CECommissioning@bmjgroup.com).

#### Call for peer reviewers

*BMJ Clinical Evidence* also needs to recruit new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity and accessibility of specific reviews within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge). Reviews are usually 1500–3000 words in length and we would ask you to review between 2–5 systematic reviews per year. The peer review process takes place throughout the year, and our turnaround time for each review is 10–14 days. In return peer reviewers receive free access to *BMJ Clinical Evidence* for 3 months for each review.

If you are interested in becoming a peer reviewer for *BMJ Clinical Evidence*, please complete the peer review questionnaire at [www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp](http://www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp)